Biliopancreatic diversion in a renal transplant patient

Obesity Surgery

Volumn 17, Issue 4, 2007, Pages 553-555

  Deogracias, Maite López ^a   Domínguez Diez, Agustin ^a   Palomar Fontanet, Rosa ^a   González Noriega, Monica ^a   Rodrigo, E ^b   Fernandez Fresnedo G ^b   Zubimendi, J A ^b   Olmedo, Francisco ^a   Gómez Fleitas, Manuel ^a   Arias, M ^a   Fernández Escalante, Carlos ^a  

^a HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^b NONE

Author keywords

Biliopancreatic diversion; Morbid obesity; Renal transplantation

Indexed keywords

ANTIHYPERTENSIVE AGENT; AZATHIOPRINE; CHOLESTEROL; CREATININE; CYCLOSPORIN A; GLUCOSE; IMMUNOSUPPRESSIVE AGENT; STEROID; TRIACYLGLYCEROL;

ADULT; ARTICLE; BILIOPANCREATIC BYPASS; CASE REPORT; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY FAILURE; CREATININE BLOOD LEVEL; FOLLOW UP; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPERURICEMIA; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY AMYLOIDOSIS; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LIVER BIOPSY; LOW DRUG DOSE; MALE; OBESITY; PRIORITY JOURNAL; QUALITY OF LIFE; SECONDARY HYPERPARATHYROIDISM; STOMACH BIOPSY; SURGICAL PATIENT; TRIACYLGLYCEROL BLOOD LEVEL; URINARY TRACT INFECTION; WEIGHT REDUCTION;

AMYLOIDOSIS; BILIOPANCREATIC DIVERSION; CYCLOSPORINE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; OBESITY, MORBID;

EID: 34249785401     PISSN: 09608923     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11695-007-9097-z     Document Type: Article

References (15)

1. Scopinaro N. Biliopancreatic diversion: mechanisms of action and long-term results. Obes Surg 2006; 16: 683-9.
2. Scopinaro N, Marinari GM, Camerini GB et al. Specific effects of biliopancreatic diversion on the major components of metabolic syndrome: a long-term follow-up study. Diabetes Care 2005; 28: 2406-11.
3. Adami G, Murelli F, Carlini F et al. Long-term effect of biliopancreatic diversion on blood pressure in hypertensive obese patients. Am J Hypertens 2005; 18: 780-4.
4. Ducloux D, Kazory A, Simula-Faivre D et al. Oneyear post-transplant weight gain is a risk factor for graft loss. Am J Transplant 2005; 5: 2922-8.
5. Kramer HJ, Saranathan A, Luke A et al. Increasing body mass index and obesity in the incident ESRD population. J Am Soc Nephrol 2006; 17: 1453-9.
6. Bach JF. Lessons for transplant immunosuppression from the usage of cyclosporine in autoimmune diseases. Transplant Proc 1994; 36: 3077-81.
7. Armstrong KA, Campbell SB, Hawley CM et al. Obesity is associated with worsening cardiovascular risk factor profiles and proteinuria progression in renal transplant recipients. Am J Transplant 2005; 5: 2710-8.
8. Hanish SI, Petersen RP, Collins BH et al. Obesity predicts increased overall complications following pancreas transplantation. Transplant Proc 2005; 37: 3564-6.
9. Cofan F, Vela E, Cleries M. Obesity in renal transplantation: analysis of 2691 patients. Transplant Proc 2005; 37: 3695-7.
10. Gore JL, Pham PT, Danovitch GM et al. Obesity and outcome following renal transplantation. Am J Transplant 2006; 6: 357-63.
11. Hibberd AD, Trevillian PR, Roger SD et al. Assessment of the bioequivalence of a generic cyclosporine A by a randomized controlled trial in stable renal recipients Transplantation 2006; 15; 81: 711-7.
12. Kasap B, Soylu A, Turkmen M et al. Effect of obesity and overweight on cyclosporine blood levels and renal functions in renal adolescent recipients. Transplant Proc 2006; 38: 463-5.
13. Ablassmaier B, Klaua S, Jacobi CA et al. Laparoscopic gastric banding after heart transplantation. Obes Surg 2002; 12: 412-5.
14. Weiss H, Nehoda H, Labeck B et al. Organ transplantation and obesity: evaluation, risks and benefits of therapeutic strategy. Obes Surg 2000; 10: 465-9.
15. Newcombe V, Blanch A, Slater GH et al. Laparoscopic adjustable gastric banding prior to renal transplantation. Obes Surg 2005; 15: 567-70.